Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389137 | 0.89 | HTR6 (0.39) | LMNAALDH1A1HTTNPSR1PKM | |
| SCHEMBL659419 | 0.87 | HTR6 (0.39) | PIK3C3HTR6 | |
| SCHEMBL109862 | 0.80 | ALDH1A1 (0.42) | LMNAALDH1A1HTTNPSR1PKM | |
| SCHEMBL18388930 | 0.75 | HTR6 (0.43) | PIK3C3HTR6BCHE | |
| SCHEMBL111538 | 0.71 | KMT2A (0.39) | ALDH1A1NPSR1MAPK1PIK3C3HTR6 | |
| SCHEMBL458128 | 0.68 | HTR6 (0.39) | NPSR1HTR6KMT2A | |
| SCHEMBL715648 | 0.66 | HTR6 (0.36) | ALDH1A1PIK3C3HTR6BCHE | |
| SCHEMBL1721268 | 0.64 | SCN9A (0.36) | PIK3C3HTR6 | |
| SCHEMBL23569703 | 0.64 | HTR6 (0.57) | ALDH1A1HTTHTR6MEN1MAPT | |
| SCHEMBL17776507 | 0.64 | TARBP2 (0.56) | LMNAALDH1A1NPSR1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10383879-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20130029985-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| EP-2424864-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029985-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | LMNA 4672/4885ALDH1A1 2100/4885HTT 3650/4885 |
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | LMNA 4445/4885ALDH1A1 2224/4885HTT 2945/4885 |
| US-10383879-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | LMNA 4445/4885ALDH1A1 2224/4885HTT 2945/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | LMNA 4445/4885ALDH1A1 2224/4885HTT 2945/4885 |
| US-20190328744-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | LMNA 4593/4885ALDH1A1 2899/4885HTT 3830/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | LMNA 1325/4885ALDH1A1 3472/4885HTT 4008/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | LMNA 4672/4885ALDH1A1 2100/4885HTT 3650/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | LMNA 4672/4885ALDH1A1 2100/4885HTT 3650/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | LMNA 4593/4885ALDH1A1 2899/4885HTT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.